StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Leerink Remains Skeptical Despite FDA Draft Questions on Sarepta (SRPT)
April 22, 2016 1:28 PM
Leerink Partners analyst Joseph Schwartz weighed in on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA released draft questions which re-ignited ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Momentum Movers
Trader Talk
Next Articles
Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
April 25, 2016 7:02 AM
Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected Halt
April 25, 2016 6:40 AM
Baird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking Move' by FDA
April 22, 2016 2:57 PM
Sarepta (SRPT) Voting Questions Rekindle Hope, but RBC Still Expects a Negative Panel
April 22, 2016 2:22 PM
FDA Draft Questions Changes Calculus on Sarepta (SRPT) Approval 'to Some Extent' - Janney Montgomery Scott
April 22, 2016 1:35 PM
Sarepta Therapeutics (SRPT) Continues Surge Higher as FDA Ads Voting Question
April 22, 2016 12:21 PM
Sarepta Therapeutics (SRPT) Sees Strong Mid-Day Upside
April 22, 2016 12:03 PM
